Background
Methods
Patients and samples
Cytogenetic and mutation analyses
Outcome measures
Western blot
Quantitative real-time reverse transcription PCR
Cell lines
Short hairpin RNA and gene overexpression constructs
Lentivirus and infection
Measurement of apoptosis and cell death
Measurement of intracellular ROS
Measurement of intracellular F2,6BP
Tumor xenografts
Statistical analyses
Results
TIGAR upregulation is associated with poor prognosis in AML patients
TIGARhigh
| TIGARlow
|
P
| |
---|---|---|---|
Age (years), median (range) | 49 (15–80) | 47 (12–86) | 0.798 |
Gender, male/female | 29/29 | 28/30 | 1.000 |
WBC, median (range) (×109/L) | 26 (0.6–291) | 34 (1.3–299) | 0.995 |
Hb, median (range) (g/L) | 79 (39–154) | 87 (39–148) | 0.398 |
PLT, median (range) (×109/L) | 42 (10–190) | 37 (2–295) | 0.190 |
PB blasts (%), median (range) | 66 (0–98) | 65 (0–96) | 0.525 |
BM blasts (%), median (range) | 75 (11.6–96.2) | 72 (24–93.6) | 0.870 |
NPM1 (+) | 25.0% (12/48) | 22.0% (11/50) | 0.726 |
CEBPA (+) | 14.6% (7/48) | 31.9% (15/47) | 0.045 |
FLT3-ITD (+) | 12.5% (6/48) | 15.7% (8/51) | 0.649 |
C-KIT (+) | 6.3 (3/48) | 6.3% (3/48) | 1.000 |
p53 mutation | 2.1% (1/48) | 2.0%(1/51) | 1.000 |
Induction | Consolidation | Case numbers | Dosage of anthracyclines (each course) |
---|---|---|---|
IA | Intermediate dose cytarabine | 74 | Idarubicin 12 mg/m2/day, IV, day 1 to 3 |
CAG | CAG | 12 | Aclarubicin 10 mg/day, IV, day 1 to 8 |
DCAG | DCAG | 23 | Aclarubicin 10 mg/day, IV, day 3 to 6 |
B
| SE | Wald |
P
| Exp (B) | 95% CI | |
---|---|---|---|---|---|---|
Age | 0.039 | 0.017 | 5.017 |
0.025
| 1.040 | 1.005 to 1.076 |
WBC | −0.004 | 0.004 | 1.250 | 0.264 | 0.996 | 0.989 to 1.003 |
Hb | 0.008 | 0.009 | 0.769 | 0.381 | 1.008 | 0.990 to 1.027 |
PLT | 0.003 | 0.003 | 1.242 | 0.265 | 1.003 | 0.997 to 1.009 |
PB blasts | −0.006 | 0.011 | 0.326 | 0.568 | 0.994 | 0.972 to 1.016 |
BM blasts | 0.029 | 0.015 | 3.584 | 0.058 | 1.030 | 0.999 to 1.061 |
Allo-SCT | 0.323 | 0.614 | 0.277 | 0.599 | 0.724 | 0.217 to 2.411 |
NPM1 | −0.197 | 0.432 | 0.209 | 0.648 | 0.821 | 0.352 to 1.914 |
CEBPA | −0.880 | 0.543 | 2.620 | 0.106 | 0.415 | 0.143 to 1.204 |
FLT3-ITD | −0.980 | 0.804 | 1.484 | 0.223 | 0.375 | 0.078 to 1.816 |
C-KIT | −12.589 | 644.378 | 0.000 | 0.984 | 0.000 | |
TIGAR | 0.868 | 0.381 | 5.200 |
0.023
| 2.383 | 1.130 to 5.025 |
Chemotherapy | 0.587 | 0.333 | 3.114 | 0.078 | 1.799 | 0.937 to 3.455 |